Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Northwest Biotherapeutics (NWBO) Operating Income (2016 - 2025)

Northwest Biotherapeutics (NWBO) has 16 years of Operating Income data on record, last reported at -$14.3 million in Q3 2025.

  • For Q3 2025, Operating Income rose 3.25% year-over-year to -$14.3 million; the TTM value through Sep 2025 reached -$64.9 million, down 2.78%, while the annual FY2024 figure was -$66.5 million, 19.82% down from the prior year.
  • Operating Income reached -$14.3 million in Q3 2025 per NWBO's latest filing, up from -$14.8 million in the prior quarter.
  • Across five years, Operating Income topped out at -$12.3 million in Q1 2022 and bottomed at -$21.1 million in Q2 2022.
  • Average Operating Income over 5 years is -$15.7 million, with a median of -$15.1 million recorded in 2023.
  • Peak YoY movement for Operating Income: tumbled 149.84% in 2021, then surged 37.22% in 2022.
  • A 5-year view of Operating Income shows it stood at -$12.4 million in 2021, then plummeted by 46.51% to -$18.2 million in 2022, then increased by 16.7% to -$15.1 million in 2023, then fell by 22.17% to -$18.5 million in 2024, then increased by 22.59% to -$14.3 million in 2025.
  • Per Business Quant database, its latest 3 readings for Operating Income were -$14.3 million in Q3 2025, -$14.8 million in Q2 2025, and -$17.3 million in Q1 2025.